A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3

We tested the principle of treating malignant ovarian tumors by vaccination against their ectopically expressed protein, zona pellucida glycoprotein (ZP) 3, using as the experimental model the granulosa cell tumors that develop in transgenic mice expressing the simian virus 40 T‐antigen under the inhibin‐α promoter (inhα/Tag). We found high ZP3 expression in granulosa cell tumors of the transgenic mice, in human surface ovarian cancer and granulosa cell lines, and in human granulosa cell tumors and their metastases. Early preventive immunization (between 2 and 5.5 mo of age) of transgenic mice with recombinant human (rh) ZP3 prevented ovarian tumorigenesis, and delayed therapeutic immunization (between 4.5 and 7 mo) reduced weights of existing tumors by 86 and 75%, respectively (P<0.001), compared to vehicle‐treated control mice. No objective side effects of the immunizations were observed. Liver metastases were found in nontreated/vehicle‐treated controls (n=7/39), but none following active rhZP3 immunizations (n=0/36; P<0.05). Immunization with rhZP3 was highly effective, as demonstrated by the induction of anti‐ZP3 antibodies, as well as proliferative responses to the ZP3 antigen. These results signal rhZP3 immunization as a novel strategy to be developed for the immunotherapy of ovarian granulosa cell tumors, as well as for that of other malignancies that may express ZP3.Rahman, N. A., Coelingh Bennink, H.J. T., Chrusciel, M., Sharp, V., Zimmerman, Y., Dina, R., Li, X., Ellonen, A., Rivero‐Müller, A., Dilworth, S., Ghaem‐Maghami, S., Vainio, O., Huhtaniemi, I. A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J. 26, 324–333 (2012). www.fasebj.org

[1]  John Kouvaris,et al.  Granulosa Cell Tumor of the Ovary: Tumor Review , 2008, Integrative cancer therapies.

[2]  R. Roden,et al.  Antigen‐specific immunotherapy of cervical and ovarian cancer , 2008, Immunological reviews.

[3]  T. Economopoulos,et al.  Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG). , 2008, Anticancer research.

[4]  Jinyao Li,et al.  Enhanced contraceptive response by co‐immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary , 2007, The journal of gene medicine.

[5]  K. Sole.  New tables allow calculation of risk of bladder cancer recurrence and progression , 2006, Nature Clinical Practice Urology.

[6]  K. Sole.  BCG therapy reduces risk of recurrence in superficial bladder cancer , 2006, Nature Clinical Practice Urology.

[7]  P. Wassarman,et al.  Mouse zona pellucida genes and glycoproteins , 2004, Cytogenetic and Genome Research.

[8]  S. Gupta,et al.  Characterization of immune response in mice to plasmid DNA encoding dog zona pellucida glycoprotein-3. , 2003, Vaccine.

[9]  I. Huhtaniemi,et al.  Ovarian Tumorigenesis in Mice Transgenic for Murine Inhibin α Subunit Promoter-Driven Simian Virus 40 T-Antigen: Ontogeny, Functional Characteristics, and Endocrine Effects1 , 2001, Biology of reproduction.

[10]  W. Schoonen,et al.  Development of Time-Resolved Immunofluorometric Assays for Rat Follicle-Stimulating Hormone and Luteinizing Hormone and Application on Sera of Cycling Rats , 2000, Biology of reproduction.

[11]  C. Seid,et al.  Expression and purification of recombinant human zona pellucida proteins. , 1999, Protein expression and purification.

[12]  I. Huhtaniemi,et al.  Hormonal regulation of proliferation of granulosa and Leydig cell lines derived from gonadal tumors of transgenic mice expressing the inhibin-α subunit promoter/simian virus 40 T-antigen fusion gene , 1999, Molecular and Cellular Endocrinology.

[13]  J. Woodruff,et al.  Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. , 1999, American journal of obstetrics and gynecology.

[14]  T. Hämäläinen,et al.  Transgenic mouse models for gonadal tumorigenesis , 1998, Molecular and Cellular Endocrinology.

[15]  R. Aitken,et al.  Evaluation of the Contraceptive Potential of Recombinant Human ZP3 and Human ZP3 Peptides in a Primate Model: Their Safety and Efficacy , 1998, American Journal of Reproductive Immunology.

[16]  C. Tropé,et al.  Current status of chemotherapy in gynecologic cancer. , 1997, Seminars in oncology.

[17]  S. Gupta,et al.  Prospects of zona pellucida glycoproteins as immunogens for contraceptive vaccine. , 1997, Human reproduction update.

[18]  J. Dehaven,et al.  Allium sativum (garlic) treatment for murine transitional cell carcinoma , 1997, Cancer.

[19]  C. Tropé,et al.  Epithelial ovarian carcinoma , 1997, The Lancet.

[20]  M. Fujime,et al.  Immunohistochemical Study of Tumor‐Infiltrating Lymphocytes Before and After Intravesical Bacillus Calmette‐Guérin Treatment for Superficial Bladder Cancer , 1997, International journal of urology : official journal of the Japanese Urological Association.

[21]  I. Huhtaniemi,et al.  Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin alpha-subunit gene. , 1996, Molecular endocrinology.

[22]  I. Huhtaniemi,et al.  The mouse inhibin α-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice , 1996, Molecular and Cellular Endocrinology.

[23]  I. Huhtaniemi,et al.  Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. , 1995, Molecular endocrinology.

[24]  T. Ganesan,et al.  Inhibin as a marker for ovarian cancer. , 1995, British Journal of Cancer.

[25]  C. Høgdall,et al.  Ovarian carcinoma serum markers and ovarian steroid activity--is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels. , 1995, European journal of obstetrics, gynecology, and reproductive biology.

[26]  H. Burger,et al.  A prospective study of inhibin in granulosa cell tumors of the ovary. , 1994, Gynecologic oncology.

[27]  K. Tung,et al.  T cell peptide of a self-protein elicits autoantibody to the protein antigen. Implications for specificity and pathogenetic role of antibody in autoimmunity. , 1993, Journal of immunology.

[28]  I. Huhtaniemi,et al.  A supersensitive immunofluorometric assay for rat luteinizing hormone. , 1993, Endocrinology.

[29]  A. Bradley,et al.  α-lnhibin is a tumour-suppressor gene with gonadal specificity in mice , 1992, Nature.

[30]  R. Idzerda,et al.  Directed expression of an oncogene to Sertoli cells in transgenic mice using mullerian inhibiting substance regulatory sequences. , 1992, Molecular endocrinology.

[31]  R. Aitken,et al.  Analysis of the contraceptive potential of antibodies against native and deglycosylated porcine ZP3 in vivo and in vitro. , 1992, Biology of reproduction.

[32]  M. Krans,et al.  Inhibin as a marker for granulosa‐cell tumors , 1990, Acta obstetricia et gynecologica Scandinavica. Supplement.

[33]  S. Millar,et al.  Vaccination with a synthetic zona pellucida peptide produces long-term contraception in female mice. , 1989, Science.

[34]  R. Yanagimachi,et al.  Ovarian histopathology of bitches immunized with porcine zonae pellucidae. , 1988, American journal of reproductive immunology and microbiology : AJRIM.

[35]  W. Beamer.  Gonadotropin, steroid, and thyroid hormone milieu of young SWR mice bearing spontaneous granulosa cell tumors. , 1986, Journal of the National Cancer Institute.

[36]  S. Kaye,et al.  Cyclophosphamide, adriamycin, and cis-platinum for the treatment of advanced granulosa cell tumor, using serum estradiol as a tumor marker. , 1986, Gynecologic oncology.

[37]  P. Wassarman,et al.  Mammalian fertilization is dependent on multiple membrane fusion events. , 2008, Methods in molecular biology.

[38]  Y. Nishi,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Establishment and Characterization of a Steroidogenic Human Granulosa-Like Tumor Cell Line, KGN, That Expresses Functional Follicle-Stimulating Hormone Receptor , 2000 .

[39]  M. Gore,et al.  Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. , 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

[40]  J. Cain,et al.  Serum inhibin and disease status in women with ovarian granulosa cell tumors. , 1997, Gynecologic oncology.

[41]  I. Huhtaniemi,et al.  Suppression of gonadotropins inhibits gonadal tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene. , 1997, Endocrinology.

[42]  M. Matzuk,et al.  Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. , 1996, Recent progress in hormone research.

[43]  I. Huhtaniemi,et al.  The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice. , 1996, Molecular and cellular endocrinology.

[44]  E Simonsen,et al.  Granulosa cell tumors of the ovary: prognostic factors and outcome. , 1994, Gynecologic oncology.

[45]  A. Bradley,et al.  Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. , 1992, Nature.

[46]  K. Tung,et al.  Autoimmune disease of the ovary induced by a ZP3 peptide from the mouse zona pellucida. , 1992, The Journal of clinical investigation.

[47]  M. Soloway.  Diagnosis and management of superficial bladder cancer. , 1989, Seminars in surgical oncology.